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We analyzed DNA duplexes modified at central guanine
residues by monofunctional Ru(II) arene complexes
[(h6-arene)Ru(II)(en)(Cl)]+ (arene = tetrahydroanthracene
or p-cymene, Ru-THA or Ru-CYM, respectively). These
two complexes were chosen as representatives of
two different classes of Ru(II) arene compounds for
which initial studies revealed different binding modes:
one that may involve DNA intercalation (tricyclic-ring
Ru-THA) and the other (mono-ring Ru-CYM) that may
not. Ru-THA is w20 times more toxic to cancer cells
than Ru-CYM. The adducts of Ru-THA and Ru-CYM
have contrasting effects on the conformation, ther-
modynamic stability, and polymerization of DNA in vi-
tro. In addition, the adducts of Ru-CYM are removed
from DNA more efficiently than those of Ru-THA. In-
terestingly, the mammalian nucleotide excision repair
system has low efficiency for excision of ruthenium
adducts compared to cisplatin intrastrand crosslinks.
Introduction
There is much current interest in the potential of ruthe-
nium complexes as new metal-based antitumor drugs
[1, 2]. Although the pharmacological target for antitu-
mor ruthenium compounds has not been unequivocally
identified, several ruthenium(III) compounds have been
found to inhibit DNA replication, exhibit mutagenic
activity, induce the SOS repair mechanism, bind to
nuclear DNA, and reduce RNA synthesis, which is con-
sistent with DNA binding of these compounds in vivo
[2]. Thus, DNA interactions of antitumor ruthenium agents
are of potential importance. Organometallic rutheni-
um(II) arene complexes of the type [(h6-arene)Ru(II)
(en)Cl][PF6] (en = ethylenediamine) constitute a rela-
tively new group of anticancer compounds [3, 4]. These
monodentate complexes appear to be novel anticancer
agents with a mechanism of action different from those
of the ruthenium(III) complexes (ImH)[trans-Ru(III)Cl4Im
(Me SO)] (Im = imidazole, NAMI-A) and (IndH)[trans-2*Correspondence: pjs01@staffmail.ed.ac.uk; brabec@ibp.czRuCl4(Ind)2] (Ind = indazole, KP1019), which are cur-
rently in clinical trials [5]. The (h6-arene)Ru(II) π bonds
in the monofunctional [(h6-arene)Ru(II)(en)(Cl)]+ com-
plexes are inert toward hydrolysis, but the chloride li-
gand is readily lost, and the complex is transformed
into the corresponding more reactive, aquated species
[6]. It has also been shown that in cell-free media ethy-
lenediamine Ru(II) arene compounds, in which arene =
biphenyl, dihydroanthracene, tetrahydroanthracene,
p-cymene, or benzene, bind preferentially to guanine
residues in natural double-helical DNA. In addition,
DNA binding of the complexes containing biphenyl, di-
hydroanthracene, or tetrahydroanthracene ligands can
involve combined coordination to G N7 and noncova-
lent, hydrophobic interactions between the arene li-
gand and DNA, which may include arene intercalation
and minor groove binding [7, 8]. In contrast, the single
hydrocarbon rings in the p-cymene and benzene ruthe-
nium complexes cannot interact with double-helical
DNA by intercalation [8]. Interestingly, adducts of the
complex containing the p-cymene ligand, which has
methyl and isopropyl substituents, distort the confor-
mation and thermally destabilize double-helical DNA
distinctly more than the adducts of the tricyclic-ring
Ru(II) arene compounds. It has been suggested that the
different character of conformational alterations in-
duced in DNA as a consequence of its global modifica-
tion, and the resulting thermal destabilization, may
affect differently further “downstream” effects of dam-
aged DNA [8] and consequently may result in different
biological effects of this new class of metal-based anti-
tumor compounds.
To achieve a rational design of novel antitumor Ru(II)
arene compounds capable of circumventing inherent or
acquired resistance to metal-based drugs already used
in the clinic, it is important to understand in detail the
differences in DNA binding properties of these new ru-
thenium complexes and their possible relationship to
cytotoxicities in different tumor cell lines. This may pro-
vide grounds for establishing new structure-pharmaco-
logical activity relationships for this class of metal-based
complexes. In this work, we have considered the activity
of two Ru(II) arene complexes from the [(h6-arene)
Ru(II)(en)(Cl)]+ family (arene = tetrahydroanthracene and
p-cymene, Ru-THA and Ru-CYM, respectively, Figure
1A) in two tumor cell lines. These two complexes were
chosen as representatives of two different classes of
Ru(II) arene compounds for which initial studies of
global modification of natural DNA revealed [8] different
binding modes: one that may involve DNA intercalation
(tricyclic-ring Ru-THA) and the other (mono-ring Ru-
CYM) that cannot interact with double-helical DNA by
intercalation. We compare the cytotoxicity data with
those for DNA binding obtained previously [8], new
data obtained in the present work relating to conforma-
tional distortions induced by single, site-specific mono-
functional adducts of the Ru(II) arene complexes in
short oligodeoxyribonucleotide duplexes, and the re-
cognition of these DNA adducts by specific proteins
and their repair, i.e., the most important factors that
Chemistry & Biology
122Figure 1. Structures of the Ruthenium Complexes and the Nucleo-
tide Sequences of the Synthetic Oligodeoxyribonucleotide Du-
plexes with the Abbreviations Used in the Present Study
(A) Structures. (a) Ru-THA; (b) Ru-CYM.
(B) Sequences. The top and bottom strands of the pair of oligonu-
cleotides are designated “top” and “bottom,” respectively. The
boldface letter in the top strand of the duplexes indicates the ru-
thenated residues.modulate the antitumor effects of platinum antitumor
drugs already used in the clinic.
Results
Chemical Probes of DNA Conformation
We demonstrated in our preceding paper [8] that Ru(II)
arene compounds bind preferentially to guanine resi-
dues in natural double-helical DNA forming monofunc-
Ftional adducts. In order to obtain information on how
these adducts affect DNA conformation, the oligonucle- (
(otide duplexes containing a site-specific monofunctional
Dadduct of Ru-THA or Ru-CYM (Figure 1A), [(h6-tetra-
thydroanthracene)Ru(II)(en)(Cl)]+ and [(h6-p-cymene)Ru(II)
s
(en)(Cl)]+, respectively, at the G residue were further an- t
alyzed by chemical probes of DNA conformation. The t
ruthenated duplex TGT(20) (Figure 1B) was treated with o
Gseveral chemical agents that are used as tools for mon-
Titoring the existence of conformations other than ca-
anonical B DNA. These agents include KMnO4 and di- (
ethyl pyrocarbonate (DEPC). They react preferentially t
with single-stranded DNA and distorted double- C
stranded DNA [9, 10]. We used for this analysis exactly t
sthe same methodology as described in detail in our re-
cent papers in which we studied DNA adducts of vari-
ous antitumor platinum drugs [9, 10], and, therefore,
these experiments are described in more detail in the a
tSupplemental Data (see the Supplemental Data avail-
able with this article online). The results demonstrated S
nin Figure 2 indicate that the distortion induced by the
nonintercalating Ru-CYM extended over at least 7 base h
cpairs (bp), whereas the distortion induced by Ru-THA
was less extensive. b
c
iIsothermal Titration Calorimetry
A calorimetric technique was employed to characterize s
tthe influence of the monofunctional adduct of Ru-THAigure 2. Chemical Probes of DNA Conformation
A) Piperidine-induced specific strand cleavage at KMnO4-modified
lanes marked with KMnO4) and DEPC-modified (lanes marked with
EPC) bases in the nonmodified TGT(20) duplex or that containing
he single, monofunctional adduct at the central G in the top
trand. The oligomer was 5#-end labeled at its top (KMnO4) or bot-
om (DEPC) strand. Lanes: ss, the nonmodified single strand; ds,
he nonmodified duplex; RuTHA, the duplex containing an adduct
f Ru-THA; RuCYM, the duplex containing an adduct of Ru-CYM;
, a Maxam-Gilbert-specific reaction for the unplatinated duplex.
he boldface letters in the sequences indicate the ruthenated G
nd complementary C residues.
B) Summary of the reactivity of chemical probes of DNA conforma-
ion. Upper panel, adduct of Ru-THA; lower panel, adduct of Ru-
YM. Filled circle, strong reactivity; half-filled circle, medium reac-
ivity; open circle, weak reactivity. The boldface letter in the top
trand of the duplexes indicates the ruthenated G residue.nd Ru-CYM on the thermal stability and energetics of
he site-specifically ruthenated 15 bp DNA duplex.
uch thermodynamic data can reveal how the ruthe-
ium adduct influences duplex stability, a property that
as been shown to play a significant role in cellular pro-
esses such as recognition of DNA damage by DNA
inding proteins and repair of this damage, i.e., the pro-
esses that may modulate potency of antitumor drugs,
ncluding metal-based cytostatics. Recently, differential
canning calorimetry (DSC) was employed to charac-
erize the influence of different crosslinks of platinum
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123antitumor drugs on the thermal stability and energetics
of 15–20 bp DNA duplexes site-specifically modified by
these drugs [11–13]. We decided to expand these
studies to oligodeoxyribonucleotide duplexes contain-
ing unique monofunctional adducts of the Ru-THA or
Ru-CYM complexes. DSC makes it possible to measure
excess heat capacity versus temperature profiles for
the thermally induced transitions of nonmodified DNA
duplexes and those containing a unique adduct of the
metal-based drug. Such thermograms are usually re-
corded with the heating rate of 60°C/hr, and after reach-
ing the maximum temperature of 95°C, the samples are
cooled at the same rate to the starting temperature of
25°C [11–13]. This implies that the duplexes containing
the unique adduct are exposed to higher temperatures
for a relatively long period of time. Therefore, we veri-
fied first the stability of the Ru(II) arene adducts at vari-
ous temperatures and found that the adducts formed
in the TGT(15) duplex by Ru-THA and Ru-CYM are sta-
ble for more than 2 hr only at temperatures lower than
50°C. Hence, it is apparent that DSC cannot be used to
analyze the duplexes containing the adducts of these
two Ru(II) arene complexes. A suitable alternative is
isothermal titration calorimetry (ITC), which makes it
possible to study the thermodynamic parameters of the
duplex formation from its two complementary single
strands over a range of temperatures including those
at which the DNA adducts of Ru(II) arene compounds
were stable for a long period of time [14].
Figure 3 shows ITC profiles of duplex formation from
the nonmodified bottom strand of the duplex TGT(15)
titrated into the complementary nonmodified top strand
of the duplex TGT(15) or the same strand containing a
single monofunctional adduct of Ru-THA or Ru-CYM atFigure 3. Isothermal Titration Calorimetry
(A and B) ITC binding isotherm for the association of the top strand
of the 15 bp TGT duplex containing a single, monofunctional ad-
duct of (A) Ru-THA or (B) Ru-CYM with the complementary (non-
modified) strand (bottom strand of the duplex TGT(15)) at 25°C in
10 mM phosphate buffer (pH 7.0) containing 50 mM NaCl. The up-
per panels show total heat released upon injecting 5 µl aliquots of
the 50 M bottom strand into a 1.4 ml reaction cell containing the
5 M top strand. The lower panels show the resultant binding iso-
therm (full squares) obtained by integrating the peak areas of each
injection. The continuous line represents the nonlinear least
squares fit of the affinity (K), enthalpy (H), and stoichiometry (n)
to a single-site binding model. For other details, see the text.25°C. It was verified that the melting temperature of the
duplexes was significantly higher than this temperature
and that the adducts of Ru-THA and Ru-CYM formed
in the TGT(15) duplex or in its single-stranded top
strand were stable for more than 24 hr. The ITC profiles
were analyzed as described in the Experimental Pro-
cedures to obtain the results listed in Table 1. Inspec-
tion of these thermodynamic parameters reveals that
the exothermic formation of the single monofunctional
adduct in the duplex TGT(15) by Ru-THA or Ru-CYM
resulted in a large decrease of the change in the en-
thalpy of duplex formation by 4.4 and 7.4 kcal/mol,
respectively. In other words, the monofunctional adduct
of Ru-THA or Ru-CYM enthalpically destabilizes the du-
plex relative to its nonmodified counterpart. In addition,
the formation of the monofunctional adducts by Ru-
THA or Ru-CYM resulted in a substantial increase in the
entropy of the duplex TGT(15) of 11.6 or 18.2 cal/K.mol
(TS = 3.6 and 5.4 kcal/mol at 25°C), respectively. In
other words, the monofunctional adduct of Ru-THA or
Ru-CYM increases the entropy of the ruthenated du-
plexes and, in this way, entropically stabilizes the du-
plex. Thus, the 4.4 or 7.4 kcal/mol enthalpic destabiliza-
tion of the TGT(15) duplex due to the monofunctional
adduct of Ru-THA or Ru-CYM is partially, but not com-
pletely, compensated by the entropic stabilization of
the duplex induced by these adducts of 3.5 or 5.4 kcal/
mol at 25°C, respectively. The net result of these enthal-
pic and entropic effects is that the formation of the
monofunctional adducts of Ru-THA and Ru-CYM with
the duplex TGT(15) at 25°C induces a decrease in du-
plex thermodynamic stability (G25) of 0.8 or 2.0 kcal/
mol, respectively, with this destabilization being enthal-
pic in origin. In this respect, the monofunctional adduct
of Ru-CYM was considerably more effective than that
of Ru-THA.
Probing by DNA Polymerase
It has been demonstrated that various DNA secondary
structures have significant effects on the processivity
of a number of prokaryotic, eukaryotic, and viral DNA
polymerases. Interestingly, with DNA templates con-
taining site-specifically placed adducts of various plati-
num compounds, a number of prokaryotic and eukary-
otic DNA polymerases were blocked but could also
traverse through the adducts depending on their char-
acter and conformational alterations induced in DNA.
Inhibition of prokaryotic DNA-dependent RNA polymer-
ase by the adducts on DNA globally modified by Ru
arene compounds, including Ru-THA and Ry-CYM, has
already been demonstrated in in vitro transcription
mapping experiments [8]. Interestingly, monofunctional
adducts of cisplatin or transplatin and those of the mo-
nodentate compounds such as chlorodiethylenetri-
amineplatinum(II) chloride ([PtCl(dien)]Cl) or [PtCl(NH3)3]Cl
terminate DNA synthesis by DNA polymerases in vitro
markedly less efficiently than crosslinks of platinum
complexes [15, 16]. It is, therefore, interesting to exam-
ine whether a DNA polymerase, which processes DNA
substrates containing monofunctional adducts of Ru-
THA or Ru-CYM, can reveal potential specific features
of conformational alterations imposed on DNA by the
monofunctional adducts of these two Ru(II) arene com-
pounds.
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124Table 1. Calorimetrically Derived Thermodynamic Parameters for the Formation of the 15 bp Nonmodified Duplexes or Those Containing
Single, Site-Specific Monofunctional Adducts of Ru-THA or Ru-CYM at 25°C
Duplex Ha (kcal/mol) Sa (cal/K.mol) G25a (kcal/mol) Kb (M−1) Nb
TGT(15) −79.3 −228 −11.3 1.98 × 108 1.08
TGT(15)·Ru-THA −74.9 −216 −10.5 3.8 × 107 1.06
TGT(15)·Ru-CYM −71.9 −210 −9.3 6 × 106 0.94
The H and S values are averages derived from three independent experiments.
aH, S, and G25 denote, respectively, the enthalpy, entropy, and free energy (at 25°C) of duplex formation.
bK and n denote, respectively, association constant and binding stoichiometry for strand association.We constructed 8-mer/23-mer primer/template non- R
imodified duplexes or those containing the monofunc-
tional adduct of Ru-THA, Ru-CYM or [PtCl(dien)]Cl in 1
cthe central TGT sequence (for sequences, see Figure
4). The first eight nucleotides on the 3# terminus of the D
a23-mer template strand were complementary to the nu-
cleotides of the 8-mer primer, and the guanine involved s
cin the monofunctional adduct of Ru-THA, Ru-CYM, or
[PtCl(dien)]Cl on the template strand was located at the a
u13th position from the 3# terminus (Figure 4). After an-
nealing the 8-mer primer to the 3# terminus of the non- p
cmodified or metallated template strand, positioning the
3# end of the primer five bases before the adduct in T
dthe template strand, we examined DNA polymerization
through the single, monofunctional adducts of Ru-THA, t
pRu-CYM, or [PtCl(dien)]Cl by a Klenow fragment of DNA
polymerase I (KF) in the presence of all four deoxyribo- t
Rnucleoside 5# triphosphates. The reaction was stopped
at various time intervals, and the products were ana- s
alyzed by using a sequencing 24% polyacrylamide
(PAA)/8 M urea gel (shown for the monofunctional ad- 1
dducts of Ru-THA and Ru-CYM in Figure 4). Polymeriza-

















CFigure 4. Primer Extension Activity of Klenow Fragment of DNA
rPolymerase I
bExperiments were conducted by incubating 8-mer/23-mer primer/
Ttemplate duplex for various times (lanes 1–5), or the template con-
taining a monofunctional adduct of Ru-THA (lanes 6–10) or of Ru- f
CYM (lanes 11–15). Timings were as follows: 1 min, lanes 1, 6, and p
11; 3 min, lanes 2, 7, and 12; 15 min, lanes 3, 8, and 13; 30 min,
lanes 4, 9, and 14; 60 min, lanes 5, 10, and 15. The pause sites p
opposite the ruthenated guanine and the preceding residues are
smarked 13 and 12, respectively (the site opposite the ruthenated
tresidue is still marked “Ru”). The nucleotide sequences of the tem-
plate and the primer are shown beneath the gels. cu-THA proceeded rapidly up to the nucleotide preced-
ng and at the sites opposite the adduct, such that the
2 and 13 nucleotide products accumulated to a signifi-
ant extent (shown in Figure 4, lanes 6–10). The larger
NA intermediates were not observed to a consider-
ble extent, whereas no intermediate products were
een with the 23-mer control template or the template
ontaining the monofunctional adduct of [PtCl(dien)]Cl
s the full-length products were formed (shown in Fig-
re 4 for control template, lanes 1–5). The full-length
roducts were also noticed with the 23-mer template
ontaining the adduct of Ru-THA (Figure 4, lanes 6–10).
his result demonstrates that the monofunctional ad-
uct of Ru-THA effectively inhibits DNA synthesis, but
ranslesion synthesis may occur. Under the same ex-
erimental conditions, DNA polymerization by KF with
he template containing the monofunctional adduct of
u-CYM proceeded up to the nucleotide preceding the
ite opposite the ruthenated G involved in the adduct
nd to the following nucleotide residue (Figure 4, lanes
1–15). There was no accumulation of shorter interme-
iates, but larger DNA intermediates (corresponding to
4 and 15 nucleotide products) and the full-length pro-
ucts were noticed. The amount of the full-length pro-
ucts increased with reaction time, but with a some-
hat lower rate compared to the polymerization with
he template containing the adduct of Ru-THA.
epair
igure 5A illustrates an experiment that measures DNA
epair synthesis by a repair-proficient HeLa cell-free ex-
ract (CFE) in pUC19 plasmid modified at rb = 0.05 by
u-THA or Ru-CYM, and for comparative purposes,
lso by cisplatin. Repair activity was monitored by
easuring the amount of incorporated radiolabeled nu-
leotide. A similar amount of undamaged pBR322 of a
lightly different size is included in the reactions to
how the background incorporation into undamaged
lasmid. This background incorporation was sub-
racted from that found for metallated pUC19 plasmid.
onsiderably different levels of damage-induced DNA
epair synthesis were detected in the plasmid modified
y Ru-THA, Ru-CYM, and cisplatin (Figures 5A and 5B).
he level of the synthesis detected in the plasmid modi-
ied by Ru-THA was w6 times lower than that in the
lasmid modified by Ru-CYM.
DNA repair synthesis can be due to various DNA re-
air mechanisms. Bulky, helix-distorting DNA adducts,
uch as those generated by various chemotherapeu-
ics, including cisplatin, are removed from DNA by nu-
leotide excision repair (NER), which is an important
DNA Modified by Antitumor Ru(II) Arene Complexes
125Figure 5. Repair DNA Synthesis and Nucleotide Excision Repair
(A and B) In vitro repair synthesis assay of the extract prepared
from the repair-proficient HeLa cell line. Repair synthesis used as
substrates nonmodified pBR322 plasmid and nonmodified pUC19
plasmid (lane C) or pUC19 plasmid modified at rb = 0.05 by cis-
platin, Ru-THA, or Ru-CYM (lanes cisPt, RuTHA, and RuCYM,
respectively). (A) Results of a typical experiment. The top panel is
a photograph of the EtBr-stained gel, and the bottom panel is the
autoradiogram of the gel showing incorporation of [α-32P]dCMP. (B)
Incorporation of dCMP into nonmodified, platinated, or ruthenated
plasmids. For all quantifications representing mean values of three
separate experiments, incorporation of radioactive material is cor-
rected for the relative DNA content in each band. The radioactivity
associated with the incorporation of [α-32P]dCMP into DNA modi-
fied by cisplatin was taken as 100%.
(C and D) Excision of the adducts of ruthenium complexes by ro-
dent excinuclease. (C) The 148 bp substrates were incubated with
CHO AA8 CFE and subsequently treated overnight with NaCN prior
to analysis in 10% PAA/8 M urea denaturing gel; lanes: 1 and 2,
control, nonmodified substrate; 3 and 4, the substrate containing
the 1,2-GG intrastrand crosslink of cisplatin; 5 and 6, monofunc-
tional adduct of Ru-THA; 7 and 8, the monofunctional adduct of
Ru-CYM. Lanes 1, 3, 5, and 7, no extract added; lanes 2, 4, 6, and
8, the substrates were incubated with CHO AA8 CFE for 40 min at
30°C. Lane M, the 20- and 30-mer markers. (D) Quantitative analy-
sis of removal of the adducts. The columns marked cisPt, RuTHA,
and RuCYM represent 1,2-GG intrastrand crosslink of cisplatin, the
monofunctional adduct of Ru-THA, and the monofunctional adduct
of Ru-CYM, respectively. The radioactivity associated with the frag-
ments excised from the duplex containing the 1,2-GG intrastrand
CL of cisplatin was taken as 100%. Data are the average of two
independent experiments performed under the same conditions.component of the mechanism underlying the biological
effects of these agents. Efficient removal of crosslinks
formed in DNA by platinum antitumor compounds has
already been reported for various NER systems, includ-
ing human and rodent excinucleases [17–20]. The result
presented in Figure 5C, lane 4 is consistent with these
reports. The major excision fragment contains 28 nu-
cleotides, and other primary excision fragments are 24–
29 nucleotides in length [17–20]. In contrast, the mono-
functional adducts of Ru-THA and Ru-CYM were also
excised by both human and rodent excinucleases
(shown for rodent excinuclease in Figures 5C and 5D),
although with a noticeably lower efficiency than the ma-
jor intrastrand crosslink of cisplatin; the adduct of Ru-CYM was excised slightly more than that of Ru-THA.
Consistent with this observation were the results of the
gel mobility shift assay analysis (Supplemental Figure
S1) employing replication protein A (RPA) (which be-
longs to the initial damage-sensing factors of eukary-
otic excision nuclease initiating repair) and DNA probes
containing the adducts of Ru-THA, Ru-CYM, or cis-
platin. The analysis performed with the substrate con-
taining the major intrastrand crosslink of cisplatin re-
vealed considerably higher binding than that performed
with the substrate containing the adduct of Ru-THA or
Ru-CYM (Supplemental Figure S1). In addition, a lower
binding of RPA to the substrate containing the adduct
of Ru-THA than to the substrate with the adduct of Ru-
CYM was observed (Supplemental Figure S1). Thus,
these results (described in detail in the Supplemental
Data) corroborate the findings in Figures 5C and 5D and
demonstrate the low efficiency of the mammalian NER
systems employed in the present work to excise Ru(II)
arene adducts and especially that of Ru-THA.
Cytotoxicity
The cytotoxic activity of the Ru(II) arene compounds
tested in the present work was evaluated as described
previously [3, 4] and has been determined in two cancer
cell lines, A2780 and HT29. The compounds were incu-
bated for 24 hr with the tumor cell lines [3, 4]. IC50 val-
ues (compound concentration that produces 50% of
cell killing) of 0.4 and 10 M were obtained in A2780
cells, and values of 3 and >100 M were obtained in
HT29 cells for Ru-THA and Ru-CYM, respectively (D.I.
Jodrell and R. Aird, personal communication). Hence,
the tricyclic-ring complex Ru-THA was considerably
more potent than the Ru-CYM complex. Thus, the ca-
pability of the Ru(II) arene complex to intercalate DNA
correlates with the noticeably enhanced activity of this
class of Ru(II) arene compounds in several cancer cell
lines.
Discussion
Our initial studies [8] suggested that Ru(II) arene com-
pounds containing multi-ring biphenyl, dihydroanthra-
cene, or tetrahydroanthracene ligands bind to DNA dif-
ferently in comparison to the complexes containing single
hydrocarbon rings, such as p-cymene or benzene. DNA
binding of the multiring Ru(II) arene complexes involves
not only coordination to G N7 together with C6O··(en)
H–bonding, but also noncovalent, hydrophobic interac-
tions between the arene ligand and DNA, which may
include arene intercalation and minor groove binding.
In contrast, the Ru arene compounds containing single
hydrocarbon rings cannot interact with double-helical
DNA by intercalation. Therefore, we tried first to find
out whether this different DNA binding mode correlates
with the cytotoxicity of the Ru(II) arene compounds in
different tumor cell lines. Interestingly, the results of the
previous [3, 4] and present work (vide supra) support
the view that the presence of an arene ligand in these
classes of ruthenium complexes that is capable of non-
covalent, hydrophobic interaction with DNA (presuma-
bly intercalation) considerably enhances the cytotoxic-
ity in a number of tumor cell lines.
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of several transition metal-based complexes is modu- g
lated by the “downstream” effects of damaged DNA, v
such as recognition of damaged DNA by specific pro- t
teins and/or repair [21, 22]. For instance, recognition of p
DNA adducts of several antitumor metal-based drugs b
and removal of these adducts from DNA is dependent r
on the character of the distortion and thermodynamic T
destabilization induced in DNA by these adducts [11, t
23]. A more detailed analysis of conformational distor- b
tions induced in DNA by Ru-THA and Ru-CYM carried a
out in the present work revealed substantial differences m
in the character of these distortions. Their analysis by c
chemical probes of DNA conformation demonstrated o
(Figure 2) that the distortion induced by the noninterca- n
lating Ru-CYM extended over at least 7 bp, whereas m
the distortion induced by Ru-THA was less extensive. p
Consistent with this observation were the results of the
ITC analysis (Figure 3 and Table 1). The association i
constants, K, for the formation of duplexes containing p
adducts of Ru-THA or Ru-CYM were 5 or 33 times t
lower, respectively, than the K value for the formation a
of the control (nonmodified) duplex (Table 1). Hence, p
the adducts of both Ru-THA and Ru-CYM thermody- g
namically destabilized DNA, with this destabilization t
being enthalpic in origin. The adduct of Ru-CYM desta- t
bilized DNA significantly more than the adduct of Ru- t
THA, whose DNA binding mode, additionally, involves l
noncovalent, hydrophobic interactions between the ar- a
ene ligand and DNA, such as arene intercalation. Vari- c
ous intercalators thermodynamically stabilize DNA t
since they lengthen and unwind DNA, increasing the R
phosphate spacing along the helix axis [24, 25]. Hence, d
it is reasonable to suggest that the higher thermo- c
dynamic stability of DNA containing the adducts of Ru- t
THA observed in the present work is associated with m
this hydrophobic interaction. f
Consistent with the different character of the adducts r
of Ru-THA and Ru-CYM and with the different impact
of these adducts on DNA conformation and stability are b
also their different effects on primer extension activity p
of KF (Figure 4). The results of the present work suggest r
that the monofunctional adducts of Ru-THA and Ru- t
CYM efficiently inhibit DNA polymerization and in dif-
s
ferent ways. These studies demonstrate that the mono-
u
functional adducts of Ru-THA and Ru-CYM constitute
sa fairly strong block to DNA synthesis catalyzed by KF;
hhowever, this block is not absolute, allowing translesion
fDNA synthesis with a limited efficiency. Hence, DNA
apolymerization appears to be inhibited by Ru(II) arene
iadducts markedly more strongly than by the adducts
uof simple monofunctional platinum(II) compounds. This
Nprovides a new dimension to the design of Ru(II) arene
ocompounds for affecting processes in tumor cells, pos-
csibly including replication or DNA repair.
iIt has been suggested [21, 22] that HMG domain pro-
pteins play a role in sensitizing cells to cisplatin. It has
obeen shown [26] that HMG domain proteins recognize
aand bind to DNA crosslinks formed by cisplatin. The
pdetails of how the binding of HMG domain proteins to
tcisplatin-modified DNA sensitize tumor cells to cis-
splatin are still not completely resolved, but possibilities
dsuch as shielding cisplatin-DNA adducts from repair or
that these proteins could be recruited from their native mranscriptional regulatory function have been sug-
ested [21, 22] as clues for how these proteins are in-
olved in the antitumor activity. In addition, an impor-
ant structural motif recognized by HMG domain
roteins on DNA modified by cisplatin is a directional
end of the helix axis toward the major groove [27]. No
ecognition of the DNA monofunctional adducts of Ru-
HA or Ru-CYM by HMGB1 protein was observed in
he present work (see the Supplemental Data). A plausi-
le explanation of this observation may be that these
dducts do not bend DNA, thus affording no structural
otif recognized by HMG domain proteins. From these
onsiderations, we could conclude that the mechanism
f antitumor activity of Ru(II) arene compounds does
ot involve recognition of its DNA adducts by HMG do-
ain proteins as a crucial step, in contrast to the pro-
osals for cisplatin and its direct analogs [21, 22].
Another important feature of the mechanism underly-
ng antitumor effects of DNA binding metal-based com-
ounds is repair of their DNA adducts [21, 28]. A persis-
ence of these DNA adducts may potentiate their
ntitumor effects in the cells sensitive to these com-
ounds [21, 22, 29]. DNA repair synthesis was investi-
ated in the present work by using the CFE from human
umor cells and DNA substrates randomly modified by
he Ru(II) arene compounds (Figures 5A and 5B). Impor-
antly, Ru-THA adducts induced a considerably lower
evel of repair synthesis than the adducts of Ru-CYM
nd also of cisplatin (Figure 5B), suggesting a less effi-
ient removal from DNA and enhanced persistence of
he adducts of more potent multi-ring and intercalating
u(II) arene compounds in comparison with the ad-
ucts of less potent and nonintercalating Ru(II) arene
ompounds. Additionally, the level of DNA repair syn-
hesis induced by the adducts of Ru-CYM was still
arkedly higher than that induced by cisplatin; this
inding is consistent with the lower cytotoxicity of this
uthenium compound (vide supra).
There are several types of DNA repair, for instance
ase excision, NER, mismatch, and recombination re-
air. The assay based on the measurement of DNA
epair synthesis may reflect the effectiveness of all of
hese repair mechanisms. Several reports have demon-
trated [30–32] that NER is a major mechanism contrib-
ting to cisplatin resistance. The examination of exci-
ion of monofunctional adducts of Ru-THA and Ru-CYM
as revealed that these adducts also can be removed
rom DNA by NER (Figures 5C and 5D), but consider-
bly less efficiently than the adducts of cisplatin. This
s in contrast to the results of DNA repair synthesis (Fig-
res 5A and 5B) and implies a less significant role of
ER in the mechanism underlying the antitumor effects
f Ru(II) arene compounds than in the mechanism of
isplatin. In other words, the results of the present work
ndicate that the adducts of Ru(II) arene compounds are
referentially removed from DNA by repair mechanisms
ther than NER, which provides additional support for
mechanism of antitumor activity of Ru(II) arene com-
ounds different from that of cisplatin. Nevertheless,
he results of both repair assays employed in the pre-
ent work (Figure 5) demonstrate clearly that the ad-
ucts of Ru-CYM, which distort and destabilize DNA
ore than the adducts of Ru-THA, are removed from
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127DNA more effectively, independent of the type of the
repair mechanism.
Hence, the character and extent of DNA distortion
induced in DNA by the adducts of Ru(II) arene com-
plexes and resulting thermodynamic destabilization of
DNA control the biological effects of this class of ruthe-
nium complexes. The results of the present work afford
further details, which allow for improving the structure-
pharmacological relationship of Ru(II) arene compounds,
and should provide a more rational basis for the design
of new antitumor ruthenium drugs and chemotherapeu-
tic strategies.
Significance
Organometallic ruthenium(II) arene complexes of the
type [(h6-arene)Ru(II)(en)Cl][PF6] (en = ethylenedia-
mine) constitute a new group of anticancer com-
pounds. To achieve a rational design of novel antitu-
mor Ru(II) arene compounds, it is important to
understand the differences in DNA binding properties
of these complexes and their possible relationship to
cytotoxicities in different tumor cell lines. In this
work, we studied the activity of two Ru(II) arene com-
plexes from the [(h6-arene)Ru(II)(en)(Cl)]+ family (ar-
ene = tetrahydroanthracene and p-cymene, Ru-THA,
and Ru-CYM, respectively) in two tumor cell lines,
conformational distortions induced by monofunc-
tional adducts of these complexes, and their recogni-
tion by DNA binding proteins and repair, i.e., the most
important factors that modulate the antitumor effects
of related platinum drugs. These two ruthenium com-
plexes were chosen as representatives of two dif-
ferent classes of Ru(II) arene compounds that modify
DNA differently: one that may interact with DNA by
intercalation (tricyclic-ring Ru-THA), and the other
(mono-ring Ru-CYM) that cannot.
The presence of the arene ligand in this class of
ruthenium complexes capable of noncovalent, hy-
drophobic interaction with DNA considerably en-
hances cytotoxicity in several tumor cell lines. An
analysis of DNA duplexes modified by Ru-THA and
Ru-CYM revealed substantial differences in the im-
pact of their monofunctional adducts on the confor-
mation and thermodynamic stability of DNA and DNA
polymerization in vitro. In addition, the adducts of Ru-
CYM are removed from DNA more efficiently than
those of Ru-THA. Interestingly, the adducts of Ru(II)
arene compounds are preferentially removed from
DNA by mechanisms other than nucleotide excision
repair. This provides additional support for a mecha-
nism underlying antitumor activity of Ru(II) arene
compounds different from that of cisplatin. Hence,
the character of DNA distortion induced in DNA by the
adducts of Ru(II) arene complexes and the resulting
thermodynamic destabilization of DNA control the bi-
ological effects of this class of ruthenium complexes.
Experimental Procedures
Starting Materials
The complexes Ru-THA and Ru-CYM (Figure 1A) were prepared by
the methods described in detail previously [3, 7]. Cisplatin, glyco-
gen, and dimethyl sulfate (DMS) were obtained from Sigma.[PtCl(dien)]Cl was kindly provided by G. Natile. The stock solutions
of the ruthenium and platinum complexes at the concentration of
5 × 10−4 M in H2O were prepared in the dark at 25°C. Plasmids
pUC19 (2686 bp) and pBR322 (4363 bp) were isolated according
to standard procedures. The synthetic oligodeoxyribonucleotides
were purchased from VBC-Genomics (Vienna, Austria) and were
purified as described previously [33]. Restriction endonucleases,
T4 polynucleotide kinase, KF, and bovine serum albumin were
purchased from New England Biolabs. A CFE was prepared from
the HeLa S3 cell line as described [18]. This extract was kindly
provided by J.T. Reardon and A. Sancar from the University of
North Carolina. Acrylamide, agarose, bis(acrylamide), ethidium bro-
mide (EtBr), urea, and NaCN were purchased from Merck KgaA.
Creatine phosphokinase and creatine phosphate were purchased
from ICN Biomedicals, Inc. The radioactive products were
purchased from Amersham.
Metallation of Oligonucleotides
The single-stranded oligonucleotides (the top, pyrimidine-rich
strands containing a single central G of the TGT(15), TGT(20), or
TGT(NER) duplexes; Figure 1B) were reacted in stoichiometric
amounts with either Ru-THA, Ru-CYM, or [PtCl(dien)]Cl. The ruthen-
ated or platinated oligonucleotides were purified by ion-exchange
fast protein liquid chromatography (FPLC). It was verified by ruthe-
nium or platinum flameless atomic absorption spectrophotometry
(FAAS) and by optical density measurements that the modified oli-
gonucleotides contained one ruthenium or platinum atom. It was
also verified by using DMS footprinting of ruthenium or platinum
on DNA [34] that one molecule of ruthenium or platinum complex
was coordinated to the N7 atom of the single G in the top strand
of each duplex. FPLC purification and FAAS measurements were
carried out on a Pharmacia Biotech FPLC System with a MonoQ
HR 5/5 column and a Unicam 939 AA spectrometer equipped with
a graphite furnace, respectively. The duplexes containing a single,
central 1,2-GG intrastrand crosslink of cisplatin in the pyrimidine-
rich top strand were prepared as described [12]. The nonmodified,
ruthenated, or platinated duplexes used in the studies of recogni-
tion by RPA protein were purified by electrophoresis on native 15%
PAA gels (mono:bis[acrylamide] ratio = 29:1).
Isothermal Titration Calorimetry
The standard isothermal titration calorimetry (ITC) buffer for these
studies contained 50 mM NaCl with 10 mM phosphate buffer
(Na2HPO4/NaH2PO4 [pH 7.0]). Sufficient quantities of ITC solutions
were prepared to perform a set of titrations of the 50 M solution
of the bottom strand of the duplex TGT(15) (for its sequence, see
Figure 1B) into the 5 M solution of the top strand of nonmodified
TGT(15) or that containing the single, site-specific monofunctional
adduct of Ru-THA or Ru-CYM at 25°C. Molar extinction coefficients
for the single-stranded oligonucleotides (related to the strands that
were 15 nucleotides long) used in ITC experiments were deter-
mined by phosphate analysis [35]. The following extinction coeffi-
cients at 260 nm and 25°C were obtained: 108,000 and 128,000
M−1·cm−1 for the upper and bottom strands of the nonmodified
TGT(15) duplex, respectively; 113,000 and 111,000 M−1·cm−1 for the
upper strand of the TGT(15) containing the single monofunctional
adduct of Ru-THA and Ru-CYM, respectively. Stock solutions of
the strands for ITC studies were prepared in the ITC buffer and
were exhaustively dialyzed against this buffer. It was verified that
enthalpies of ITC injections of each individual oligomer into buffer,
of buffer into buffer, and of excess oligomer into a solution of du-
plex were all the same as water into water injections, within error.
From these data, it was concluded that effects of any solvent mis-
matching are negligible. Titrations were carried out on a VP-ITC
instrument (MicroCal LLC, Northampton, MA). For each titration,
the top strand of the nonmodified TGT(15) duplex or that containing
the single, site-specific adduct of Ru-THA or RuCYM was loaded
into the 1.4 ml sample cell, and the complementary oligomer (bot-
tom strand of the duplex TGT(15)) was loaded into the 300 µl injec-
tion syringe. The stirring rate of the injection syringe was 400 rpm,
and samples were equilibrated thermally prior to a titration until the
baseline had leveled off and the rms noise was less than 0.015
cal·s−1. A typical titration consisted of 50 injections of 5 µl each,
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128with 3 min between injections. Data from individual titrations were t
tanalyzed by using the Origin 5.0 software package (Origin, North-
ampton, MA) to extract the relevant thermodynamic parameters t
d(the enthalpy change [H], the entropy change [S], the stoichiom-
etry [n], and the equilibrium constant [K] for strand association). b
a
Inhibition of DNA Polymerization
We investigated DNA polymerization using the templates site-
Sspecifically modified by Ru-THA or Ru-CYM by KF. The DNA poly-
Amerase I class of enzymes has served as the prototype for studies
fon structural and biochemical mechanisms of DNA replication [36,
e37]. The 23-mer templates containing a single monofunctional ad-
sduct of Ru-THA or Ru-CYM were prepared in the same way as
hdescribed above. The eight-mer DNA primer was complementary
to the 3# terminus of the 23-mer template. The DNA substrates
were formed by annealing templates and 5#-end-labeled primers at
a molar ratio of 3:1. All experiments were performed at 25°C in a A
volume of 50 µl in a buffer containing 50 mM Tris-HCl (pH 7.4), 10
mM MgCl2, 50 g/ml BSA, 25 M dATP, 25 M dCTP, 25 M dGTP, T
25 M TTP and 0.5 U KF. Reactions were terminated by the addi- R
tion of EDTA so that its resulting concentration was 20 M and by o
heating at 100°C for 30 s. Products were resolved on a denaturing T
24% PAA/8 M urea gel and then visualized and quantified by using c
the FUJIFILM bio-imaging analyzer and AIDA image analyzer a
software. (
s
tRepair Synthesis by Human Cell Extracts
mRepair DNA synthesis of CFEs was assayed by using pUC19 and
spBR322 plasmids. Each reaction of 50 µl contained 250 ng non-
tmodified pBR322 and 250 ng nonmodified or platinated pUC19; 2
wmM ATP; 30 mM KCl; 0.5 mg/ml creatine phosphokinase (rabbit
muscle); 20 mM of each dGMP, dCTP, and TTP; 8 mM dATP; 74
kBq [α-32P]dAMP in the buffer composed of 40 mM HEPES-KOH R
(pH 7.5), 5 mM MgCl2, 0.5 mM dithiothreitol, 22 mM creatine phos- R
phate, 1.4 mg/ml bovine serum albumin, and 150 g CFE. Reac- A
tions were incubated for 3 hr at 25°C and terminated by adding P
EDTA to a final concentration of 20 mM, SDS to 0.6%, and protein-
ase K to 250 g/ml and then incubating for 30 min. The products R
were extracted with 1 volume 1:1 phenol:chloroform. The DNA was
precipitated from the aqueous layer by the addition of 1/50 volume
5 M NaCl, 5 mg glycogen, and 2.5 volumes ethanol. After 20 min of
incubation on dry ice and centrifugation at 12,000 × g for 30 min at
4°C, the pellet was washed with 0.5 ml 70% ethanol and dried in a
vacuum centrifuge. DNA was finally linearized before electrophore-
sis on a 1% agarose gel containing 0.3 mg/ml EtBr. The basic prin-
ciples of this assay are shown schematically in Supplemental Fig-
ure S2A.
Nucleotide Excision Assay
The 149 bp substrates containing a single monofunctional adduct
of Ru-THA or Ru-CYM were assembled from three oligonucleotide
duplexes. The central duplex was TGT(NER) duplex (shown in Fig-
ure 1B) to which two duplexes (arms) with random base pair se-
quences with overhangs partially overlapping those of the modified
duplex were ligated (one to each side) by T4 DNA ligase. The top
strand of the modified central duplexes were 5#-end labeled with
32P before ligation. Substrates containing a single, central 1,2-GG
intrastrand crosslink of cisplatin were prepared in a similar way to
that described previously [38]. Full-length substrates (nonmodified,
containing the monofunctional adduct of Ru-THA or Ru-CYM or the
1,2-intrastrand crosslink of cisplatin) were separated from unli-
gated products on a denaturing 6% PAA gel, purified by electroelu-
tion, reannealed, and stored in annealing buffer (50 mM Tris-HCl
[pH 7.9], 100 mM NaCl, 10 mM MgCl2, and 1 mM dithiothreitol)
at 20°C. In vitro repair of monofunctional adducts of Ru(II) arene
complexes and of the 1,2-intrastrand crosslink of cisplatin was
measured in an excision assay as described previously [38], with
minor modifications. The reaction mixtures (25 l) contained 10
fmol radiolabeled DNA, 50 g CFE, 20 M dATP, 20 M dCTP, 20
M dGTP, and 20 M TTP in reaction buffer (23 mM HEPES [pH
7.9], 44 mM KCl, 4.8 mM MgCl2, 0.16 mM EDTA, 0.52 mM dithi-
othreitol, 1.5 mM ATP, 5 g bovine serum albumin, and 2.5% glyc-
1erol) and were incubated at 30°C for 40 min. DNA was depro-einized and precipitated by ethanol. Reaction products were
reated overnight with 0.4 M NaCN (pH 10–11) at 45°C and precipi-
ated by ethanol prior to resolution on the gels. The excision pro-
ucts were separated on denaturing 10% PAA gels and visualized
y using the PhosphorImager. The basic principles of this assay
re shown schematically in Supplemental Figure S2B.
upplemental Data
description of the experiments with chemical probes of DNA con-
ormation, recognition by HMGB1 and RPA proteins, corresponding
xperimental procedures, and the basic principles of repair DNA
ynthesis and nucleotide excision repair assays are available at
ttp://www.chembiol.com/cgi/content/full/12/1/121/DC1/.
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